PRA

United Kingdom
United Kingdom
SEARCH FILTERS
Time filter
Source Type

NORFOLK, Va., May 26, 2017 (GLOBE NEWSWIRE) -- PRA Group, Inc. (Nasdaq:PRAA), a global leader in acquiring and collecting nonperforming loans, today announced the closing of its previously announced offering of $300 million aggregate principal amount of 3.50% convertible senior notes due 2023 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).  In addition, PRA announced that the initial purchasers fully exercised their option to purchase an additional $45 million in aggregate principal amount of the notes. The net proceeds from the sale of the notes, including proceeds resulting from the exercise of the initial purchasers’ option to purchase an additional $45 million in aggregate principal amount of the notes, are approximately $335.4 million, after deducting discounts, commissions and estimated offering expenses. The notes are unsecured, senior obligations of PRA Group and pay interest semiannually at a rate of 3.50% per annum. The notes will mature on June 1, 2023, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding March 1, 2023, the notes will be convertible only upon the occurrence of specified events; on and after March 1, 2023, until the close of business on the scheduled trading day immediately preceding the maturity date, the notes will be convertible at any time. The conversion rate for the notes is initially 21.6275 shares per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $46.24 per share of common stock, and is subject to adjustment in certain circumstances. The initial conversion price represents a premium of approximately 35.0% to the $34.25 per share closing price of PRA Group’s common stock on May 22, 2017, the date on which PRA Group entered into the agreement with the initial purchasers regarding the purchase of the notes. Upon conversion, the notes may be settled in cash, shares of PRA Group’s common stock or any combination thereof, at PRA Group’s election.  The notes are redeemable, in whole or in part, at PRA Group’s option at any time, and from time to time, on or after June 1, 2021, at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of PRA Group’s common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date PRA Group sends the related redemption notice. This announcement is neither an offer to sell, nor a solicitation of an offer to buy, any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offer of these securities will be made only by means of a private offering memorandum. The offer and sale of the notes and the shares of common stock, if any, issuable upon conversion of the notes, have not been and will not be registered under the Securities Act or any state securities laws, and unless so registered, the notes and such shares may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws. As a global leader in acquiring and collecting nonperforming loans, PRA Group, Inc. returns capital to banks and other creditors to help expand financial services for consumers in the Americas and Europe. With more than 4,000 employees worldwide, PRA Group companies collaborate with customers to help them resolve their debt and provide a broad range of additional revenue and recovery services to business clients. Statements made herein that are not historical in nature, including PRA Group’s or its management’s intentions, beliefs, expectations, projections, plans or predictions of the future, are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this press release are based upon management's current beliefs, estimates, assumptions and expectations of PRA Group’s future operations and financial and economic performance, taking into account currently available information. These statements are not statements of historical fact or guarantees of future performance, and there can be no assurance that anticipated events will transpire or that our expectations will prove to be correct. Forward-looking statements involve risks and uncertainties, some of which are not currently known to PRA Group. Actual events or results may differ materially from those expressed or implied in any such forward-looking statements as a result of various factors. Additional risk factors and other risks that are described from time to time in PRA Group’s filings with the Securities and Exchange Commission including but not limited to PRA Group’s annual reports on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K, which are available through PRA Group’s website and contain a detailed discussion of PRA Group’s business, including risks and uncertainties that may affect future results. Due to such uncertainties and risks, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of today. Information in this press release may be superseded by recent information or statements, which may be disclosed in later press releases, subsequent filings with the Securities and Exchange Commission or otherwise. Except as required by law, PRA Group assumes no obligation to publicly update or revise its forward-looking statements contained herein to reflect any change in PRA Group’s expectations with regard thereto or to reflect any change in events, conditions or circumstances on which any such forward-looking statements are based, in whole or in part.


News Article | May 9, 2017
Site: globenewswire.com

NORFOLK, Va., May 09, 2017 (GLOBE NEWSWIRE) -- PRA Group (Nasdaq:PRAA), a global leader in acquiring and collecting nonperforming loans, today reported its financial results for the first quarter of 2017.  The company reported diluted earnings per share of $1.03 versus $0.69 in the first quarter of 2016, including the gain from the sale of the Company’s Government Services business in the first quarter of 2017.  “PRA’s cash collections in the first quarter exceeded our expectations while cash operating expenses remained controlled.  We are pleased with the progress made in increasing our collector workforce in the U.S. to the appropriate level.  Both our existing collector workforce and our new hires continue to impress us with their work ethic and commitment to compliance,” said Steve Fredrickson, chairman and chief executive officer, PRA Group.  “Our cash efficiency ratio, measured as cash receipts less operating expenses divided by cash receipts, of 61% continues to compare well with previous years even with the impact of our current regulatory environment with its greater costs and negative impact on revenue.  We are also pleased with our first quarter investment, particularly in the U.S., where we see gradually improving volumes and pricing.” Conference Call Information PRA Group will hold a conference call today at 5:00 p.m. ET to discuss results with institutional investors and stock analysts.  To listen to a webcast of the call, visit http://ir.pragroup.com/events.cfm.   To listen by phone, call 888-695-7639 in the U.S. or 970-315-0482 outside the U.S.  The conference ID is 14428598.  To listen to a replay of the call until May 16, 2017, call 855-859-2056 in the U.S. or 404-537-3406 outside the U.S. and use conference ID 14428598. About PRA Group As a global leader in acquiring and collecting nonperforming loans, PRA Group returns capital to banks and other creditors to help expand financial services for consumers in the Americas and Europe. With more than 4,000 employees worldwide, PRA Group companies collaborate with customers to help them resolve their debt and provide a broad range of additional revenue and recovery services to businesses. For more information, please visit www.pragroup.com. About Forward Looking Statements Statements made herein which are not historical in nature, including PRA Group’s or its management's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this press release are based upon management's current beliefs, estimates, assumptions and expectations of PRA Group’s future operations and financial and economic performance, taking into account currently available information. These statements are not statements of historical fact or guarantees of future performance, and there can be no assurance that anticipated events will transpire or that our expectations will prove to be correct. Forward-looking statements involve risks and uncertainties, some of which are not currently known to PRA Group. Actual events or results may differ materially from those expressed or implied in any such forward-looking statements as a result of various factors, including risk factors and other risks that are described from time to time in PRA Group’s filings with the Securities and Exchange Commission including but not limited to PRA Group’s annual reports on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K, which are available through PRA Group's website and contain a detailed discussion of PRA Group's business, including risks and uncertainties that may affect future results. Due to such uncertainties and risks, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of today. Information in this press release may be superseded by recent information or statements, which may be disclosed in later press releases, subsequent filings with the Securities and Exchange Commission or otherwise. Except as required by law, PRA assumes no obligation to publicly update or revise its forward-looking statements contained herein to reflect any change in PRA Group’s expectations with regard thereto or to reflect any change in events, conditions or circumstances on which any such forward-looking statements are based, in whole or in part.


News Article | May 9, 2017
Site: globenewswire.com

NORFOLK, Va., May 09, 2017 (GLOBE NEWSWIRE) -- PRA Group (Nasdaq:PRAA), a global leader in acquiring and collecting nonperforming loans, today reported its financial results for the first quarter of 2017.  The company reported diluted earnings per share of $1.03 versus $0.69 in the first quarter of 2016, including the gain from the sale of the Company’s Government Services business in the first quarter of 2017.  “PRA’s cash collections in the first quarter exceeded our expectations while cash operating expenses remained controlled.  We are pleased with the progress made in increasing our collector workforce in the U.S. to the appropriate level.  Both our existing collector workforce and our new hires continue to impress us with their work ethic and commitment to compliance,” said Steve Fredrickson, chairman and chief executive officer, PRA Group.  “Our cash efficiency ratio, measured as cash receipts less operating expenses divided by cash receipts, of 61% continues to compare well with previous years even with the impact of our current regulatory environment with its greater costs and negative impact on revenue.  We are also pleased with our first quarter investment, particularly in the U.S., where we see gradually improving volumes and pricing.” Conference Call Information PRA Group will hold a conference call today at 5:00 p.m. ET to discuss results with institutional investors and stock analysts.  To listen to a webcast of the call, visit http://ir.pragroup.com/events.cfm.   To listen by phone, call 888-695-7639 in the U.S. or 970-315-0482 outside the U.S.  The conference ID is 14428598.  To listen to a replay of the call until May 16, 2017, call 855-859-2056 in the U.S. or 404-537-3406 outside the U.S. and use conference ID 14428598. About PRA Group As a global leader in acquiring and collecting nonperforming loans, PRA Group returns capital to banks and other creditors to help expand financial services for consumers in the Americas and Europe. With more than 4,000 employees worldwide, PRA Group companies collaborate with customers to help them resolve their debt and provide a broad range of additional revenue and recovery services to businesses. For more information, please visit www.pragroup.com. About Forward Looking Statements Statements made herein which are not historical in nature, including PRA Group’s or its management's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this press release are based upon management's current beliefs, estimates, assumptions and expectations of PRA Group’s future operations and financial and economic performance, taking into account currently available information. These statements are not statements of historical fact or guarantees of future performance, and there can be no assurance that anticipated events will transpire or that our expectations will prove to be correct. Forward-looking statements involve risks and uncertainties, some of which are not currently known to PRA Group. Actual events or results may differ materially from those expressed or implied in any such forward-looking statements as a result of various factors, including risk factors and other risks that are described from time to time in PRA Group’s filings with the Securities and Exchange Commission including but not limited to PRA Group’s annual reports on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K, which are available through PRA Group's website and contain a detailed discussion of PRA Group's business, including risks and uncertainties that may affect future results. Due to such uncertainties and risks, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of today. Information in this press release may be superseded by recent information or statements, which may be disclosed in later press releases, subsequent filings with the Securities and Exchange Commission or otherwise. Except as required by law, PRA assumes no obligation to publicly update or revise its forward-looking statements contained herein to reflect any change in PRA Group’s expectations with regard thereto or to reflect any change in events, conditions or circumstances on which any such forward-looking statements are based, in whole or in part.


News Article | May 9, 2017
Site: globenewswire.com

NORFOLK, Va., May 09, 2017 (GLOBE NEWSWIRE) -- PRA Group (Nasdaq:PRAA), a global leader in acquiring and collecting nonperforming loans, today reported its financial results for the first quarter of 2017.  The company reported diluted earnings per share of $1.03 versus $0.69 in the first quarter of 2016, including the gain from the sale of the Company’s Government Services business in the first quarter of 2017.  “PRA’s cash collections in the first quarter exceeded our expectations while cash operating expenses remained controlled.  We are pleased with the progress made in increasing our collector workforce in the U.S. to the appropriate level.  Both our existing collector workforce and our new hires continue to impress us with their work ethic and commitment to compliance,” said Steve Fredrickson, chairman and chief executive officer, PRA Group.  “Our cash efficiency ratio, measured as cash receipts less operating expenses divided by cash receipts, of 61% continues to compare well with previous years even with the impact of our current regulatory environment with its greater costs and negative impact on revenue.  We are also pleased with our first quarter investment, particularly in the U.S., where we see gradually improving volumes and pricing.” Conference Call Information PRA Group will hold a conference call today at 5:00 p.m. ET to discuss results with institutional investors and stock analysts.  To listen to a webcast of the call, visit http://ir.pragroup.com/events.cfm.   To listen by phone, call 888-695-7639 in the U.S. or 970-315-0482 outside the U.S.  The conference ID is 14428598.  To listen to a replay of the call until May 16, 2017, call 855-859-2056 in the U.S. or 404-537-3406 outside the U.S. and use conference ID 14428598. About PRA Group As a global leader in acquiring and collecting nonperforming loans, PRA Group returns capital to banks and other creditors to help expand financial services for consumers in the Americas and Europe. With more than 4,000 employees worldwide, PRA Group companies collaborate with customers to help them resolve their debt and provide a broad range of additional revenue and recovery services to businesses. For more information, please visit www.pragroup.com. About Forward Looking Statements Statements made herein which are not historical in nature, including PRA Group’s or its management's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this press release are based upon management's current beliefs, estimates, assumptions and expectations of PRA Group’s future operations and financial and economic performance, taking into account currently available information. These statements are not statements of historical fact or guarantees of future performance, and there can be no assurance that anticipated events will transpire or that our expectations will prove to be correct. Forward-looking statements involve risks and uncertainties, some of which are not currently known to PRA Group. Actual events or results may differ materially from those expressed or implied in any such forward-looking statements as a result of various factors, including risk factors and other risks that are described from time to time in PRA Group’s filings with the Securities and Exchange Commission including but not limited to PRA Group’s annual reports on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K, which are available through PRA Group's website and contain a detailed discussion of PRA Group's business, including risks and uncertainties that may affect future results. Due to such uncertainties and risks, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of today. Information in this press release may be superseded by recent information or statements, which may be disclosed in later press releases, subsequent filings with the Securities and Exchange Commission or otherwise. Except as required by law, PRA assumes no obligation to publicly update or revise its forward-looking statements contained herein to reflect any change in PRA Group’s expectations with regard thereto or to reflect any change in events, conditions or circumstances on which any such forward-looking statements are based, in whole or in part.


News Article | May 10, 2017
Site: www.prweb.com

Continuing Education Company(CEC), a leader in Primary Care Live Continuing Medical Education (CME), is celebrating 25 years of presenting quality education to Primary Care clinicians. In honor of their 25th anniversary, CEC will be offering a free 20 credit online CME course to all attendees of their 2017 live conferences. The complimentary course will be available through CEC's online portal, CME365, and will enable CEC conference attendees to earn a total of up to 40 credits. This offer is valid only for participants who attend all the days of the live conference they select. Access to the online CME course is sent to registrants after they have attended and successfully completed the live conference. The online CME course is not transferable and is not valid if they cancel their registration or are a no show at the live conference. Webcast participants are not eligible for this offer. Walter Ejnes, President of CEC says "Continuing Education Company's free 20 credit online CME course offering is our way of saying thank you to the thousands of medical professionals who have supported us for the past 25 years." CME365 offers live streaming webcasts of CEC's conferences as well as online courses in Primary Care, Urgent Care and Pulmonology. All the online courses are fully accredited and feature the same high quality education as the live Continuing Medical Education conferences that Continuing Education Company offers throughout the year. Continuing Education Company, Inc. (CEC) is an independent, non-profit, 501 (c)(3) continuing medical education organization. They have been developing and presenting continuing medical education programs for over 25 years. Their mission is to develop and provide educational opportunities to improve the skills and knowledge of medical and healthcare professionals. They accomplish this mission by offering American Academy of Family Physicians (AAFP), AMA PRA Category 1 Credits™ and ABIM MOC accredited live CME conferences and online courses. The mission of Continuing Education Company, Inc. (CEC) is to improve public health by developing and providing educational opportunities to advance the skills and knowledge of physicians and other healthcare professionals. This mission is accomplished by assisting healthcare professionals in assessing their educational needs and providing them with evidence-based education which meet those needs. For more information please visit the company website, http://www.cmemeeting.org. __title__ online link]


News Article | May 8, 2017
Site: www.prweb.com

Plastic Surgery Associates is excited to announce that Heather Furnas, MD, and Francisco Canales, MD, have been asked to present at the upcoming Aesthetic Meeting. Held in San Diego, at the San Diego Convention Center, the annual event will run from April 27-May 2. Drs. Furnas and Canales will lend their expertise to the Premier Global Hot Topics session, speaking on genital rejuvenation. Hosted by the American Society for Aesthetic Plastic Surgery (ASAPS), the Aesthetic Meeting is known for providing a unique opportunity for top plastic surgeons and aesthetic professionals to share in the latest trends and developments in cosmetic medicine. This year marks the 50th anniversary the event, which first met in Venice, Italy in 1967. The organization now boasts a membership of more than 2,200 international professionals from the fields of facial plastic surgery, plastic surgery, dermatology and oculoplastic surgery. ASAPS Aesthetic Meeting will consist of a five-day conference, filled with a variety of educational presentations, board-room breakout lectures, lunch and learn sessions and a Corporate Satellite Symposia. The highly interactive and engaging learning experience will include presentations from leading experts on selected topics selected on the face, breast and body, as well as patient safety and practice management. All of those in attendance have the opportunity to earn up 48.75 AMA PRA Category 1 CME credits. During the Premier Global Hot Topics session, held on Friday, April 28, Drs. Furnas and Canales will present on the advances of female genital plastic surgery. Their talks will cover the viewpoints of both function and aesthetic changes achieved through genital rejuvenation. The surgeons will expand on the innovative ways that new, cutting-edge technology plays an important role today for improving a woman’s quality of life. Additionally, Dr. Furnas will provide the welcome message and introductions at the the 4th Annual Women Aesthetic Surgeon’s Symposium, held on April 27, as part of the Aesthetic Meeting. The scheduled presentations of Dr. Furnas and Dr. Canales will cover a variety of genital rejuvenation topics, including: Dr. Furnas co-founded Santa Rosa’s Plastic Surgery Associates in 1992 with her husband, Dr. Canales. As avid lecturers, educators and writers, Dr. Furnas and Dr. Canales often speaks on a variety of plastic surgery topics at conventions around the United States and internationally. Both board certified by the American Board of Plastic Surgery, they are current members of the California Society of Plastic Surgeons, the American Society of Plastic Surgeons, and the American Society for Aesthetic Plastic Surgery. Details on the 2017 Aesthetic Meeting in San Diego, can be found on the ASAPS website or by calling 562.799.2356. Registration will be open the entire meeting, during regular business hours. Get more information on Dr. Furnas or Dr. Canales by calling Plastic Surgery Associates at 707.537.2111 or filling out an online Contact Us form. For patient convenience, Plastic Surgery Associates has two locations, in Santa Rosa and Novato, California.


News Article | May 9, 2017
Site: www.prweb.com

PAINWeekEnd (PWE) on June 3 and 4 at the Nashville Marriott at Vanderbilt University, 2555 West End Avenue, will be an educational and exciting 2-day program providing busy clinicians and allied healthcare practitioners with 12.0 hours of relevant, practical instruction in the management of chronic pain. Specialized CME in pain management is required by the Tennessee Board of Medical Examiners for providers of intractable pain management. At PWE Nashville, attendees can earn up to 12.0 AMA PRA Category 1 credits. An attendee of a recent PAINWeekEnd conference said of Dr. David Glick and his Pain Pathophysiology Unraveled course: “Very dynamic speaker, easy to listen to & understand. Open to questions & available for discussion throughout the course.” Dr. Glick will be presenting that talk, as well as Pain Diagnostics: Clinical Pearls to Improve Common Tests for Pain at PWE Nashville. Other courses include (and are subject to change) A Caress or a Slap? Understanding Sensory Amplification Systems in Chronic Pain; Nonopioid Analgesics: Antidepressants, Adjuvant Therapies, and Muscle Relaxants; Can Opioids be Rationally Prescribed for Chronic Pain?; Not for Human Consumption: New Drugs of Abuse and Their Detection; Evidence-Based Approaches to Chronic Pain Management: Time to Reconsider the Benefit of Technophilism?; The Complex Pain Patient; Embrace 2017 Practice Changes and Patient Education: Overview of Critical Pain Management Practice Issues; Reefer Madness: Taking the Insanity Out of Medical Cannabinoids; Cost Containment; and Get Your Specimens in Order: How to Avoid Bad Company and Tame the Paper Beast Associated With Testing Drugs of Abuse. Commercially supported activities—addressing a range of product, disease state, and medical information topics—will also be presented. Online registration fee for this PAINWeekEnd Conference: $199. PAINWeekEnd registrants may register for the PAINWeek National Conference, September 5-9, in Las Vegas, for $200 off the current online published price. PAINWeekEnd is provided by Global Education Group. About Global Education Group: Global Education Group focuses on producing partnership-based CME for healthcare practitioners. The Global team works with a select group of medical education companies, associations, academic institutions and healthcare facilities to develop and accredit live healthcare conferences and workshops as well as online activities. With each partnership or joint providership, Global brings accreditation expertise, project management excellence and grant funding intelligence. Based in Littleton, Colo., Global has accreditation with commendation from the ACCME. Global also holds accreditations to offer continuing education for nurses, nurse practitioners, pharmacists, dietitians, dentists and psychologists. Global is a division of Ultimate Medical Academy.


News Article | May 12, 2017
Site: www.prweb.com

In the United States, cardiovascular diseases claim more lives than all forms of cancer combined. Currently, more than 1 in 3 adults live with one or more types of cardiovascular disease. The Long Island Heart: State-of-the-Art Cardiovascular Care for the Clinician conference welcomes national and international experts in the field of cardiovascular care to a 2-day meeting. Attendees will have an opportunity to interact with these experts, access critical updates, and evaluate the emerging advances in the diagnostics and therapeutics for cardiovascular disease. The conference will be held at the Melville Marriott Long Island Hotel in Melville, NY on Friday, May 19, 2017, and Saturday, May 20, 2017. “We designed The Long Island Heart: State-of-the-Art Cardiovascular Care for the Clinician conference to meet the educational needs of the practitioners across the spectrum of care of patients with heart diseases,” said Javed Butler, MD, MPH, MBA, FACC, FAHA. “Specialist and generalist doctors, nurses, and other clinicians involved in the care of these patients will have access to critical updates and international experts. Our goal is to improve care for cardiovascular patients in Long Island.” The 2-day symposium features several Keynote discussions and a series of presentations that cover the spectrum of cardiovascular disease including: Conference attendees will enjoy complimentary breakfast, lunch, and snacks, as well as opportunities to view exhibitor displays. There is no fee for this educational activity. For more information or to register, visit: http://www.longislandheart.org. The Long Island Heart: State-of-the-Art Cardiovascular Care for the Clinician is endorsed by the Heart Failure Society of America and the New York Chapter of the American College of Cardiology. The meeting is approved for 11.75 AMA PRA Category 1 Credits™ for physicians and 11.75 hours of participation for continuing education for allied health professionals. ***


News Article | May 11, 2017
Site: www.prweb.com

Myeloproliferative Neoplasms (MPNs) are a family of related blood cancers in which the individuals bone marrow makes too many red blood cells, white blood cells, or platelets. The most common forms of MPNs are polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and chronic myeloid leukemia (CML). Local cancer organizations have come together to help healthcare providers, patients, and families dealing with MPNs. The fourth annual Spring to Life Conference on Hematologic Malignancies, sponsored by New York Oncology Hematology, will be held at the Albany Marriott Hotel, Albany, NY on Saturday, May 20, 2017, from 7:30 am – 3:15 pm. This one-day CME-certified conference will bring together healthcare professionals and members of the community—including patients, survivors, family members, and caregivers—to gain an up-to-date understanding of blood cancers, including the state-of-the-art science behind treatment, clinical management, ongoing translational research, and emerging therapies. “Our Spring to Life conference each year highlights a different focus in the broad spectrum of hematologic malignancies or blood cancers and brings regional expertise to our community,” explains Ira Zackon, MD, New York Oncology Hematology and Conference Chair and Moderator. “Continued education at the local community level is critical to maintaining the highest quality and leading edge of health care. This year’s conference highlights this in particular, in focusing on less common diseases that do not get as much attention. Similarly, our afternoon session this year for patients, families, and community is focused on the Caregiver, the partner in health and life who also can receive less attention. These afternoon sessions continue to gain in reputation as meaningful and impactful engagements on living through the cancer experience.” The 2017 conference will focus on myeloproliferative neoplasms (MPNs), including presentations from those touched by cancer; as well as experts from New York Oncology Hematology, PC (NYOH) Albany Medical College, the Dana-Farber Cancer Institute, and Harvard Medical School. “At Leukemia & Lymphoma Society (LLS) our mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families," said Jennifer McGarry, Leukemia & Lymphoma Society Director, Patient Access Volunteer Development. “The Spring To Life Conference on Hematologic Malignancies provides a wonderful opportunity for patients and caregivers to come together, share their experiences, and work together to improve care.” The event is divided into two, half-day sessions: The symposium is hosted by New York Oncology Hematology, the region’s largest provider of community cancer care. It is accredited by Center for Emergency Medical Education (CEME) for 3.75 AMA PRA Category 1 Credits ™. The Oncology Nursing Society (ONS) will award 3.75 contact hours (based on a 60-minute contact hour) to registered nurses who complete the educational activity. Conference attendees will enjoy complimentary breakfast, light lunch, and snacks, as well as opportunities to view exhibitor displays. There is no fee for this educational activity. For more information or to register, visit: http://www.spring2lifeheme.org. About New York Oncology Hematology New York Oncology Hematology (NYOH) is the region’s leading provider of community-based cancer care and services. With seven convenient locations, a team of 36 physicians, and more than 300 oncology professionals, NYOH has been delivering world-class cancer care to the Capital Region and surrounding communities for more than 30 years. Through its affiliation with The US Oncology Network, one of the nation’s largest cancer treatment and research networks, NYOH offers the latest breakthroughs, treatments, and technologies – right here at home. About The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society ® (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services. Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. The Upstate NY/VT Chapter is located in Albany, NY.


PRA Health Sciences is one of the world's leading global contract research organizations by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 13,000 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. VAL-083 is a "first-in-class," small-molecule chemotherapeutic that demonstrated clinical activity against a range of cancers including GBM in historical clinical trials sponsored by the U.S. National Cancer Institutes (NCI). DelMar has demonstrated that VAL-083's anti-tumor activity against GBM is unaffected by the expression of MGMT and MMR in vitro.  Further details can be found at http://www.delmarpharma.com/scientific-publications.html. VAL-083 has received an orphan drug designation in Europe for the treatment of malignant gliomas and the U.S. FDA Office of Orphan Products has granted an orphan designation to VAL-083 for the treatment of glioma, medulloblastoma and ovarian cancer. Based on historic clinical trials run by the NCI, the modern Phase 1/2 dose finding trial run by DelMar in GBM (ASCO 2016), and recent guidance from the FDA, the Company has embarked on Phase 2 or 3 trials for VAL-083 across recurrent and newly diagnosed GBM. DelMar has announced plans to advance VAL-083 into a controlled Phase 3 tudy in emozolomide- vastin ecurrent GBM ("STAR-3") to evaluate overall survival versus salvage chemotherapy for GBM patients who have previously failed both temozolomide and bevacizumab (Avastin™) and for whom there exists no approved treatment option; a Phase 2 trial (with MD Anderson Cancer Center) in first recurrence GBM patients prior to bevacizumab therapy is currently enrolling; and a separate international Phase 2 trial for newly diagnosed MGMT-unmethylated GBM is planned. DelMar believes that data from its clinical trials, if successful, will form the basis of a new treatment paradigm for the vast majority of GBM patients whose tumors exhibit features that make them unlikely to respond to currently available therapies. GBM is the most common and aggressive primary brain cancer. Current standard of care includes surgery, radiation and treatment with temozolomide (TMZ), however nearly all tumors recur and the prognosis for recurrent GBM is dismal. Most GBM tumors have unmethylated promoter status for MGMT. Second-line treatment with anti-angiogenic agent bevacizumab has not improved overall survival (OS) and 5-year survival is less than 3%. VAL-083 (dianhydrogalactitol) is a first-in-class bi-functional DNA-targeting agent that induces interstrand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cell death in GBM cell lines and GBM cancer stem cells, independent of MGMT or MMR status in vitro. VAL-083 readily crosses the blood-brain barrier and accumulates in brain tumor tissue. Our recent Phase 1/2 clinical trial in recurrent GBM patients failing both TMZ and bevacizumab, suggested that VAL-083 offers clinically meaningful survival benefits for patients with recurrent GBM and pinpointed a new dosing regimen (40 mg/m2/d on days 1,2,3 of a 21-day cycle) which was well-tolerated and was selected for study in subsequent GBM trials. These trials include, i) an ongoing single-arm, biomarker driven, Phase 2 study to determine if VAL-083 treatment of MGMT-unmethylated adult GBM patients at first recurrence/progression, prior to bevacizumab improves overall survival, compared to historical control with lomustine (clinicaltrials.gov identifier: NCT02717962) ii) A pivotal controlled Phase 3 tudy in emozolomide- vastin ecurrent GBM ("STAR-3") to evaluate the overall survival of VAL-083 versus salvage chemotherapy for GBM patients who have previously failed both temozolomide and bevacizumab (Avastin™).The control arm will consist of a limited number of salvage chemotherapies currently used in bevacizumab-failed GBM. If successful, this study will serve as the basis for a New Drug Application (NDA) submission for VAL-083. iii) A single arm, biomarker driven, Phase 2 study to confirm the tolerability and efficacy of VAL-083 in combination with radiotherapy in newly diagnosed MGMT-unmethylated GBM patients whose tumors are known to express high MGMT levels. The results of these studies may support a new treatment paradigm in chemotherapeutic regimens for the treatment of GBM. DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. DelMar's VAL-083 is currently undergoing clinical trials in the U.S. as a potential new therapy for GBM. VAL-083 has been extensively studied by the U.S. National Cancer Institutes, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients. For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+. PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 13,000 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delmar-formalizes-collaboration-with-pra-health-sciences-for-phase-3-trial-of-val-083-in-recurrent-glioblastoma-multiforme-gbm-300455809.html

Loading PRA collaborators
Loading PRA collaborators